Drug Trial Radar · NCT07486310
Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Mar 1, 2026
Primary completion
Mar 1, 2028
Study completion Jun 1, 2029
Sponsor
- Lead sponsor
- Guangdong Provincial People's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, multicenter, open-label, randomized controlled clinical trial, planned to enroll 30 patients with advanced gastric cancer and peritoneal metastasis. It aims to evaluate the safety and efficacy of systemic therapy plus Pressurized Intra-Peritoneal Aerosol Virus (PIPAV) with VRT106 compared to systemic therapy plus Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC).
Conditions
- Advanced Gastric Cancer
Interventions
Doxorubicin (Adriamycin)Drug
Doxorubicin (Adriamycin)
VRT106Drug
VRT106
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: From the screening period to 28 days after the last intraperitoneal perfusion treatment during the follow-up period
- Incidence of serious adverse eventsTime frame: From the screening period to 28 days after the last intraperitoneal perfusion treatment during the follow-up period
- Eastern Cooperative Oncology Group Performance statusTime frame: From the screening period to 28 days after the last intraperitoneal perfusion treatment during the follow-up period
- Surgical complicationsTime frame: From the screening period to 28 days after the last intraperitoneal perfusion treatment during the follow-up period
- Postoperative pain score (Visual Analogue Scale/VAS score)Time frame: At the beginning of Cycle 1 (each cycle lasting 28 days), at the beginning of Cycle 2 (each cycle lasting 28 days), and at the beginning of Cycle 3 (each cycle lasting 28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
No. 106, Zhongshan 2nd Road, Yuexiu District, Guangzhou
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.